Kornimate/medical-research-clean huggingface dataset:
questionnaire for the assessment of risk factors associated with endometriosis in adolescent women with endometriosis

Conditions: Endometriosis

Summary: a number of risk factors that may be associated with endometriosis in adolescents (medical history and symptoms) are reported in the literature, but no overall estimate of disease risk has been developed. providing a tool for assessing risk factors associated with endometriosis in adolescents by estimating disease risk could aid the clinician in diagnosis and reduce diagnostic delay

although more than 60% of adult women with endometriosis report that their painful symptoms appeared before the age of 20, early diagnosis, particularly in adolescent girls, is still a challenge for doctors. the reasons for this delay include inadequate knowledge of the disease among healthcare professionals, the social and health normalisation of menstrual pain, and the peculiar aspects of the disease in adolescent patients. the adolescent patient with endometriosis presents particular anamnestic, familial and personal risk factors, as well as peculiar symptoms such as non-specific abdominal pain, acyclic pelvic pain, gastrointestinal symptoms, migraine, in addition to those classically reported in adulthood. it may therefore be useful to identify a predictive model of the onset of endometriosis based on the risk factors currently recognised in the literature (anamnestic data) and on the results of a questionnaire to be submitted to adult women (aged between 20 and 50 years), with endometriosis (group 1) and without a diagnosis of endometriosis (group 2), concerning symptoms experienced in adolescence

Eligibility criteria:
inclusion criteria: * women of childbearing age between 20 and 50 years * clinical and ultrasound diagnosis of endometriosis for the study group and exclusion of endometriosis for the control group (examination and ultrasound performed according to the idea study criteria) * acquisition of informed consent for participation in the study and processing of personal data exclusion criteria: - women suffering from other conditions responsible for pelvic pain (uterine fibromatosis, current or previous pelvic inflammatory disease, ovarian cysts of a non-endometriotic nature, irritable bowel syndrome, inflammatory bowel disease, interstitial cystitis)

Keywords: endometriosis gynaecology questionnaire risk factors painful symptoms
effect of cpap on abnormal gastroesophageal reflux and lung inflammation in ipf

Conditions: Idiopathic Pulmonary Fibrosis; Obstructive Sleep Apnea; Gastro Esophageal Reflux

Summary: this study will evaluate the effect of cpap therapy on esophageal ph and lung inflammation in patients with idiopathic pulmonary fibrosis (ipf) and sleep apnea.

participants in this study will have an overnight sleep study done while wearing a 24 hour ph monitor in the esophagus. if the participant has sleep apnea, he or she will be randomly assigned to receive either cpap treatment or no cpap treatment. after 4-8 weeks, the participant will have another overnight sleep study with 24 hour ph monitoring. blood will also be collected at both time points and again after 6 months to measure biomarkers that are related to lung inflammation.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of ipf based on the 2018 ipf guidelines * high likelihood of osa based on the stop-bang measure, with a score of 3 or greater * patients on nintedanib, or in whom nintedanib will be initiated prior to enrollment in the study * able to participated in 24hr ph monitoring * able to comply with cpap treatment * able to provide written informed consent prior to any study procedures * willing to complete all study measurements and assessments in compliance with the protocol exclusion criteria: * interstitial lung disease caused by conditions other than ipf * severe concomitant illness limiting life expectancy (\< 1 year) * residual lung volume \> or equal to 120% of predicted * obstructive lung disease: fev1/fvc ratio \< 0.70 * current drug or alcohol dependence * patients who are unable to tolerate nintedanib * patients who are unable to use cpap or are unwilling to participate in the 24 hr ph probe placement * patients who were diagnosed with recent ipf exacerbation within 4 weeks of enrollment (may be rescheduled for enrollment once recovered) * patients who have had prior nasal surgery or trauma that would make ph probe placement difficult * patients on anticoagulation (aspirin is not an exclusion)

Keywords: ipf osa gerd
assessing the burden of perioperative atrial fibrillation in patients undergoing cardiac surgery

Conditions: Atrial Fibrillation; Cardiac Surgery

Summary: background and significance: in the united states approximately 220,000 patients undergo cardiac surgery per annum. among potential complications, the incidence of atrial fibrillation (af) is estimated at 30 - 60 %, and therefore presents the most common adverse event after cardiac surgery. multiple complications may be associated with af: patients are usually subject to an increased length-of-stay in the intensive care unit and in the hospital. furthermore, the risk for stroke and development of long-term af is elevated, while further anticoagulation is required putting the patient at risk for bleeding. on average, an additional $10,000 - $20,000 is spent for each patient with af. however, the exact burden of postoperative af still remains unknown. specific aims of research project: 1. to collect data from an electrocardiogram (ekg) monitoring patch, we aim to accurately determine the prevalence of atrial fibrillation in patients undergoing cardiac surgery at our center. 2. to collect data on epidemiological characteristics to investigate risk factors for developing perioperative atrial fibrillation in patients undergoing cardiac surgery. this will allow us to create robust risk prediction models.


Eligibility criteria:
inclusion criteria: * elective open heart surgery * age \> 20 years exclusion criteria: * refusal to participate (patient or health care proxy) * participation in other pharmacological trials * lack of data or poor data quality which cannot be analyzed for any heart rhythm in 80% of the postoperative study period.

Keywords: wearable device
comparison of outcomes in asleep and awake dbs with a directional electrode

Conditions: Parkinson Disease; Deep Brain Stimulation

Summary: to compare the clinical outcome of patients with parkinson's disease (pd) treated with directional deep brain (ddbs) stimulation undergoing subthalamic deep brain stimulation operation (stn-dbs) under general anesthesia versus local anesthesia.

to compare the clinical outcome of patients with parkinson's disease (pd) treated with directional deep brain (ddbs) stimulation undergoing subthalamic deep brain stimulation operation (stn-dbs) under general anesthesia versus local anesthesia. in awake group, 10 patients with parkinson's disease were treated with st jude medical/abbott infinity dbs system, and the electrode implantation and testing were performed while the patients were awake. in asleep group, 14 patients with parkinson's disease were treated with st jude medical/abbott infinity dbs system, and the electrode implantation were performed while the patients were under general anesthesia. the clinical outcome of the dbs treatment, possible adverse effects and the electrode placement will be compared within these two groups.

Eligibility criteria:
inclusion criteria: advanced parkinson's disease * the clinical decision of dbs treatment * the clinical inclusion criteria of dbs treatment: * drug-resistant tremor * severe daily motor fluctuations or dyskinesia in despite of the optimal oral medication * an improvement of updrs iii scores over 30 % in levodopa challenge test. exclusion criteria: * the general exclusion criteria for dbs treatment: * a major depression * on-going psychosis * a significant brain atrophy observed in a brain mri * a suspicion of atypical parkinsonism * marked cognitive decline.
trial of iv ntg for cd after second stage arrest for the prevention of uterine extension

Conditions: Prolonged Second Stage of Labor

Summary: randomized controlled clinical trial of iv nitroglycerin at cesarean delivery for second stage arrest of descent to prevent or uterine extension at the hysterectomy site.

intravenous nitroglycerin resulting in uterine relaxation has been standardly utilized for various obstetrics conditions, e.g. breech extraction of second twin in vaginal deliveries, uterine relaxation after tachysystole in labor, prior to external cephalic version, and during difficult fetal extraction during cesarean delivery for arrest of descent in labor. currently the use of nitroglycerin is at equipoise in obstetrics for difficult cesarean delivery after second stage arrest in labor. the clinical trial will randomize women who undergo cesarean delivery for second stage arrest in labor to receive iv nitroglycerin vs saline at the time of hysterotomy. the primary outcomes will be maternal: uterine extension, blood loss, total fetal extraction time, surgical time; neonatal: cord gases at delivery, apgar scores, admission to neonatal intensive care unit.

Eligibility criteria:
inclusion criteria: women 37weeks or greater gestation diagnosed with second stage arrest of descent undergoing cesarean delivery - exclusion criteria: elective, active phase arrest cesarean delivery, successful operative vaginal delivery -
validation of a nics method using the culture medium

Conditions: Chromosome Abnormality; Abnormality

Summary: this study aims to validate a non-invasive method of chromosomal screening (nics), based on the multiple annealing and looping based amplification cycles- next-generation sequencing (malbac-ngs) technology, in order to determine the chromosomal endowment of a blastocyst from the dna of the embryonic culture medium. the chromosomal status of the embryo from an embryo biopsy of trophoectoderm will be established (usual clinical practice), the chromosomal endowment from the dna of the embryonic culture medium will be determined, and the results using the nics and the conventional invasive method (preimplantation genetic testing for aneuploidy \[pgt-a\]) will be compared.


Eligibility criteria:
inclusion criteria: * treatment by oocyte donation or own oocyte nd preimplantation genetic screening of aneuploidies (pgt-a). * embryonic cryopreservation. * informed consent signature exclusion criteria: * embryo transfer without embryo freezing * embryonic block. * bad embryo quality.

Keywords: diagnosis reproduction chromosomal endowment
pad combination therapy followed by thal/dex for relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: prospective multicenter phase 2 study using pad and thal/dex combination sequentially.

although the overall survival was improved with the introduction of high dose therapy with autologous hematopoetic stem cell transplantation,it remains as a incurable disease. most patients ultimately relapse. recenlty, targeted therapy using novel agents, such as bortezomib and thalidomide, shows the possibility of improved in this situation. among them, pad (velcade, adriamycin,dexamethasone) showed highest response rate. pad does not show any cross resiatance with another effective combination, thalidomide plus dexamethasone. we desined prospective multicenter phase 2 study using these combination sequentially.

Eligibility criteria:
inclusion criteria: * patients with multiple myeloma who relapsed after at least 1 lines of therapy including high dose thearapy with autologous stem cell transplantation and chemotherapy. * presence of measureble disease : serum m-protein \> 1g/dl or urine m-protein \> 400mg/day * age \< 75 * performance status \</= ecog 2 * expected survival \> 6 months * who signs the informed consent exclusion criteria: * known hypersensitivity to thalidomide or dexamethasone * known refractoriness to thalidomide + dexamethasone * previous velcade therapy * sepsis * woman in reproductive age * serum creatinine \> 2 mg/dl ; 24 hour creatinine clearance \< 30 ml/min; past medical history of kidney transplatation * peripheral neuropathy \>/= grade 2 * recurrent dvt or pulmonary embolism * cardiac ejection fraction \<0.5 : severe conduction disorder * hepatic dysfunction (ast or alt ≥ x 5 upper normal) or active hepatitis * active ulcers in gastrofiberscope

Keywords: multiple myeloma relapsed
esicm unite covid-19 project (unite-covid)

Conditions: COVID-19 Infection

Summary: covid-19 is arguably the biggest challenge critical care medicine has been confronted with since its conception. critical care services around the world are flooded by patients presenting with severe respiratory failure who require prolonged treatment in the icu. despite the support provided, outcomes are poor, particularly in ventilated patients. many unanswered questions remain regarding the pathophysiology of covid-19, particularly in severely ill patients. no evidence-based treatment is currently available, yet different often experimental therapies are administered to patients. as experience grows, new phenotypes are recognized, and unreported complications are observed in the most severely ill patients. although many registries are currently including patients, few of them focus on icu patients and their specific treatments and newly observed complications and challenges. although the pandemic may appear on its return in many countries that are now easing the restrictions that were put in place to limit the spread of the disease, it can be expected that covid-19 will be a continued challenge in icus globally until a safe and effective vaccine is found. efforts to study the disease should continue in order to advance our understanding of the disease as well as improve treatment options.

this is a multicenter, international, anonymized point prevalence study. patients who were present in the icu on the day in april 2020 with the highest number of covid-19 patients in the unit. data can be entered in the database until july 2020. retrospective data collection and entry is allowed. subjects believed to fulfill all eligibility criteria, and none of the exclusion criteria, detailed in the relevant section of this protocol, will be included in the study. data will be entered in the database anonymously. data will consist of two core elements: 1. center data (to be completed once) 2. patient data for different domains with specific, highly relevant and un(der)explored icu research questions, an focused data set is to be completed. these domains include: 1. respiratory 2. coagulation and thrombo-embolic events 3. infectious complications 4. rehabilitation 5. renal

Eligibility criteria:
inclusion criteria: * patient is present in an icu or in any other place of the hospital under the care of the critical care team on the day between 15th february 2020 and 15th june 2020 with the highest number of covid-19 patients in the unit. the exact date can be decided by the local investigator. * covid-19 confirmed diagnosis through pcr or equivalent diagnostic technique exclusion criteria: * any of the following is regarded as a criterion for exclusion from the study: sars-cov2 positive without covid-19

Keywords: covid-19 infection inflammation respiratory distress coagulation thromboembolus rehabilitation renal cardiac mobilization
study evaluating lamictal extended-release therapy added to current seizure treatments in patients with partial seizures

Conditions: Epilepsy; Epilepsy, Partial

Summary: this study is being conducted to compare the efficacy and safety of lamictal (lamotrigine) extended-release with placebo in the treatment of partial seizures. lamictal extended-release is an investigational drug. placebo tablets look like lamictal extended-release tablets but do not contain active medication. in this study, lamictal extended-release or placebo tablets will be added to current seizure treatments.


Eligibility criteria:
inclusion criteria: * diagnosis of epilepsy with partial seizures for more than 24 weeks. * must experience at least 8 partial seizures during an 8-week baseline phase. * must currently be receiving treatment with a stable regimen of one or two antiepileptic drugs for at least four weeks. * patient or parent/caregiver must be willing and able to maintain a written daily seizure diary. exclusion criteria: * previous treatment with lamotrigine. * exhibits any primary generalized seizures. * receiving treatment with felbamate or currently following the ketogenic diet. * pregnant, breastfeeding, or planning to become pregnant.

Keywords: partial seizures epilepsy antiepileptic drugs anticonvulsants lamictal seizures lamotrigine
efficacy and safety of nefecon in patients with primary iga (immunoglobulin a) nephropathy

Conditions: Primary IgA Nephropathy

Summary: the overall aim of the study is to evaluate the efficacy, safety, and tolerability of nefecon 16 mg per day in the treatment of patients with primary igan (immunoglobulin a nephropathy) at risk of progressing to end-stage renal disease (esrd), despite maximum tolerated treatment with renin-angiotensin system (ras) blockade using angiotensin converting enzyme inhibitors (aceis) or angiotensin ii type i receptor blockers (arbs).

this is a phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of oral nefecon compared to matching placebo in patients with primary igan on a background of optimized ras inhibitor therapy. the study will consist of 2 parts, part a and part b. part a will include a 9 month blinded treatment period, and a 3-month follow up period. part b of the study will consist of a 12-month observational follow up period; no study drug will be administered during part b. part a and b will be blinded. safety will be monitored by an independent data safety monitoring board.

Eligibility criteria:
inclusion criteria: 1. female or male patients ≥18 years 2. biopsy-verified iga nephropathy 3. stable dose of ras inhibitor therapy (aceis and/or arbs) at the maximum allowed dose or maximum tolerated dose (mtd) according to the 2012 kdigo (kidney disease: improving global outcomes) guidelines 4. urine protein creatinine ratio ≥1 g/24hr 5. egfr ≥35 ml/min per 1.73 m2 and ≤90 ml/min per 1.73 m2 using the chronic kidney diseae epidemiology collaboration (ckd-epi) formula 6. willing and able to give informed consent exclusion criteria: 1. systemic diseases that may cause mesangial iga deposition. 2. patients who have undergone a kidney transplant. 3. patients with acute or chronic infectious disease including hepatitis, tuberculosis, human immunodeficiency virus (hiv), and chronic urinary tract infections. 4. patients with liver cirrhosis, as assessed by the investigator. 5. patients with a diagnosis of type 1 or type 2 diabetes mellitus which is poorly controlled. 6. patients with history of unstable angina, class iii or iv congestive heart failure, and/or clinically significant arrhythmia, as judged by the investigator; 7. patients with unacceptable blood pressure control defined as a blood pressure consistently above national guidelines for proteinuric renal disease, as assessed by the investigator 8. patients with diagnosed malignancy within the past 5 years.

Keywords: iga nephropathy
reflex excitability in post-stroke stiff-knee gait

Conditions: Stroke; Chronic Stroke; Gait, Hemiplegic; Gait, Spastic; Gait Disorder, Sensorimotor; Gait Disorders, Neurologic; Walking, Difficulty

Summary: the purpose of this study is to examine the reflex excitability of the rectus femoris in individuals with and without post-stroke stiff-knee gait. we use electrical stimulation of the peripheral nerve innervating the rectus femoris for a well-controlled reflex stimulus. we are investigating whether reflex excitability of the rectus femoris correlates with gait kinematics.

the purpose of this study is to investigate the role of hyperreflexia in post-stroke stiff-knee gait function. in one aim,

Eligibility criteria:
inclusion criteria: * aged at least 18 * premorbidly independent * if post-stroke, mild to moderate impairment determined by standard practices per the physical therapist * able to continuously walk for 30 minutes * if post-stroke, reduced knee flexion during walking relative to unimpaired side * if post-stroke, hemiparesis * ability to provide informed consent exclusion criteria: * no history of serious lower limb musculoskeletal injury * no functionally relevant osteoarthritis and weight-bearing restrictions * no functionally relevant polyneuropathy * no functionally relevant cognitive impairment * no functionally relevant vision impairment
standard versus transepithelial corneal crosslinking

Conditions: Keratoconus

Summary: the gold standard corneal crosslinking (cxl) technique involves the initial step of epithelial removal, in order to achieve a sufficient treatment effect (meaning: stabilisation of progressive keratoconus (kc). our aim is to evaluate the effects of transepithelial cxl (te-cxl), whereby the epithelium is left intact and the cornea is instead treated by a solution composed of 0.1% riboflavin, combined with enhancers, after which standard cxl is performed. this solution seems to facilitate riboflavin penetration into the corneal stroma through the intact epithelium. the investigators expect to achieve a similar effect of te-cxl with the advantage of a faster healing time and less risk of infections.


Eligibility criteria:
inclusion criteria: * documented progressive kc (by pentacam and/or corneal topography imaging). * a clear central cornea. * a minimal corneal thickness of ≥ 400 µm at the thinnest corneal location (pentacam imaging). * minimal snellen corrected distance visual acuity of ≥ 0.4. * patient age of ≥ 18 years. for this research study, the inclusion parameters will be the same as mentioned above, with the following additional inclusion criteria: * documented progression of kc, as demonstrated by anterior segment imaging and/or corneal topography: o defined an increase in maximal keratometry, steepest keratometry, mean keratometry or topographic cylinder value by ≥ 0.5 d over the previous 6 months and/or a decrease in thinnest pachymetry * documented progression of kc defined by increase in refractive cylinder of ≥ 0.5 d over the previous 6 months exclusion criteria: * presence of corneal scars. * history of epithelial healing problems. * presence of previous ocular infection (such as herpes keratitis). * patients who are pregnant and/or breastfeeding.